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Abstract.  Thrombospondin (TSP) forms specific com- 
plexes with transforming  growth factor-fl (TGF-/~) in 
the ot granule releasate of platelets and these 
TSP-TGF-/~  complexes inhibit the growth of bovine 
aortic endothelial cells (BAE).  In these studies, we re- 
port that TSP stripped of associated TGF-/~ (sTSP)  re- 
tained growth inhibitory activity which was partially 
reversed by a neutralizing  antibody specific for TGF-~. 
Since BAE cells secrete latent TGF-/3,  we determined 
whether sTSP activates the latent TGF-/~ secreted by 
BAE cells.  Cells were cultured with or without sTSP 
and then the conditioned medium was tested for the 
ability to support TGF-/3-dependent normal rat kidney 
(NRK) colony formation in soft agar.  Medium condi- 
tioned with sTSP showed a dose- and time-dependent 
ability to stimulate BAE-secreted TGF-/~ activity, 
reaching maximal activation by 1-2 h with 0.4 #g/ml 
(0.9 nM) sTSP. The sTSP-mediated stimulation of 
TGF-/~ activity is not dependent on serum factors and 
is not a general property of extracellular matrix mole- 
cules.  The sTSP-mediated stimulation of TGF-~ activ- 
ity was blocked by a mAb specific for sTSP and by 
neutralizing  antibodies to TGF-/L  Activation of BAE 
cell secreted latent TGF-/~ by sTSP can occur in the 
absence of cells and apparently does not require inter- 
actions with cell surface molecules, since in condi- 
tioned medium removed from cells and then incubated 
with sTSP, activation occurs with kinetics and at levels 
similar to what is seen when sTSP is incubated in the 
presence of cells.  Serine proteases such as plasmin are 
not involved in sTSP-mediated activation of TGF-B. 
Factors that regulate the conversion of latent to active 
TGF-/3 are keys to controlling TGF-/~ activity. These 
data suggest that TSP is a potent physiologic regulator 
of TGF-/3 activation. 
T 
GF-/3 is a member of a family of growth,  differentia- 
tion, and morphogenesis autocrine and paracrine fac- 
tors (3, 26). TGF-/3 can affect diverse cellular func- 
tions in virtually all cell types. Depending on the cell types 
and its extracellular  environment,  these effects can be either 
positive or negative.  TGF-/3 inhibits the proliferation  of en- 
dothelial  cells in vitro (31), but stimulates  angiogenesis  in 
vivo (39). TGF-/~ has also been shown to enhance or inhibit 
the proliferation of fibroblasts depending on the nature of the 
substrate and the mitogens present (3). Myoblast differentia- 
tion can also be induced or blocked by TGF-/~ depending  on 
the availability  of mitogens (25, 45). 
TGF-~I  is a  disulfide-linked  homodimer that  is synthe- 
sized as part of a latent precursor molecule (26). The latent 
precursor molecule is 390 amino acids in length and consists 
of an NH2-terminal 278-amino acid latency-associated  pep- 
tide  (LAP) 1  and  the  COOH-terminal  112  amino  acids 
which constitute the active domain (15-17).  The proregion 
of TGF-3 is unique in that it remains non-covalently attached 
1. Abbrevian'ons used in this paper: BAE, bovine aortic endothelial; bFGF, 
basic FGF;  LAP,  latency  associated peptide;  NRK,  normal rat kidney; 
sTSP, TSP stripped of associated TGF-/~; TSP, thrombospondin. 
to the active region after intracellular  proteolytic processing 
and secretion (17). Association  of the LAP with the mature 
peptide region confers latency:  the LAP-associated growth 
factor is unable to interact with its cellular receptors. The 
LAP  contains  three  N-linked  glycosylation  sites,  two of 
which have mannose-6-phosphate  residues (8, 27, 38). These 
carbohydrate structures may be important for latency since 
endoglycosidase F  treatment  leads to activation  of TGF-/~ 
(27). The disulfide-bonded  dimeric structure of LAP is criti- 
cal for latency,  since site-directed  mutagenesis  of critical 
cysteine residues (cys 223, 225) in the LAP abolishes activity 
(9).  The active domain  contains  nine  conserved cysteine 
residues that  participate  in  inter-  and intrachain  disulfide 
bonding (28). 
TGF-/3 is secreted by most cell types as a latent complex 
(28, 37). Since TGF-/3 synthesis and TGF-/3 receptor expres- 
sion are not highly regulated,  primary regulation  of TGF-/~ 
activity occurs by controlling conversion of the latent TGF-/~ 
complex to the active molecule. Physiochemical  activation 
can occur by extremes of pH, heat,  chaotropic agents,  and 
deglycosylation  (6, 27, 28,  37).  Activation  in vivo is more 
complex and not well understood.  There is evidence from 
cell culture models that activation may occur through bind- 
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(12, 21), by plasmin-mediated proteolytic processing (4, 23, 
40,  41),  and/or by processing in acidic cellular microen- 
vironments (20). In some systems, activation of  latent TGF-13 
by plasmin is relatively inefficient (41). In addition, there are 
reports of  TGF-/3 activation occurring independently of  these 
mechanisms  (19).  These  results  suggest  that  additional 
mechanisms of latent TGF-~/activation may exist. 
We have shown previously that thrombospondin (TSP), a 
disulfide-linked trimer (450,000  daltons) present in connec- 
tive tissues and in platelet c~ granules,  is associated with 
TGF-13 as an active complex in the releasate of stimulated 
platelets (5, 14, 30, 34). TSP is synthesized and secreted by 
cells in vitro, where it is then able to bind various cellular 
receptors and/or become incorporated into the extracellular 
matrix (reviewed in 5, 14, 30).  TSP is present transiently in 
wound environments and its synthesis is rapidly induced by 
growth factors, including TGF-13. TSP, like TGF-/3, has var- 
ied effects on cell growth and differentiation. TSP stimulates 
the proliferation of fibroblasts (36) and smooth muscle cells 
(24),  and in contrast,  it  inhibits the proliferation of en- 
dothelial cells (2, 42). TSP may also serve as both an attach- 
ment protein and an anti-adhesive molecule as shown by its 
ability to cause disassembly of focal adhesions in endothelial 
cells (32). 
In the present studies, we show that TSP activates latent 
TGF-~ secreted by bovine aortic endothelial (BAE) cells in 
culture. TSP-mediated activation of TGF-13 occurs indepen- 
dently of plasmin activity and does not require interactions 
with cell surface molecules. Based on these data, we propose 
that TSP activates latent TGF-/3 through a novel mechanism. 
Furthermore, TSP-TGF-13 interactions may act as a physio- 
logic means of regulating TGF-j3 activity. 
Materials and Methods 
Thrombospandin Purification 
TSP was purified as previously described (34). Briefly, 8-10 U of fresh hu- 
man platelets were purchased from the Birmingham American Red Cross 
and washed with Hepes wash buffer (10%  ACD, 0.05  M  Hepes, 0.15  M 
NaCI, and 5 mM Dextrose, pH 7.6). The platelets were thrombin-stimulated 
and the platelet releasate was applied to a beparin-Sepharose CL-6B (Phar- 
macia, Piscataway,  NJ) affinity column pre-equilibrated with TBS-C (0.01 
M Tris-HCl, 0.15 M NaCI, 0.1 mM CaC1),  pH 7.4.  The bound TSP was 
eluted with 0.55 M NaC1/TBS  with 1 mM CaC1 and applied to a A0.5 M 
gel  filtration  column  (Bio-Rad  Laboratories,  Richmond,  CA)  pre- 
equilibrated with TBS-C, pH 11, to remove associated TGF-/~. Purity was 
assessed by SDS-PAGE using Coomassie blue or silver staining. No con- 
taminating TGF-/~ activity was found associated with sTSP in normal rat 
kidney (NRK) soft agar colony formation assays. 
Cells 
BAE cells were isolated from aortas obtained at a local abattoir, and were 
characterized by DIl-AcLDL and staining for Factor VIII antigen. Cells 
were cultured in DME (Cell-Gro, Mediatech, Herndon, VA) supplemented 
with 4.5 g/liter glucose, 2 mM glutamine, and 20% FBS (Hyclone Labora- 
tories, Logan, UT) as previously described (32). Clone 49F of NRK cells 
(American 'I~pe Culture Collection, Rockville, MD) were provided by Dr. 
Lynn-Allen Hoffmann, UW-Madison. Stocks were cultured in DME sup- 
plemented with 4.5 g/liter glucose, 2 mM giutamine, and 10% calf serum 
(CS) (Hyclone Laboratories, Logan, UT) as described (1). Calf serum was 
tested and chosen for low levels of active TGF-/~. Mink lung epithelial cells 
(CCL 64)  (MvlLu) were cultured in MEM  (Cell-Gro,  Mediatech) sup- 
plemented with 4.5 g/liter glucose, 2 mM glutamine, and 10% FBS. CHO 
cells were provided by Dr. Jeff Esko (University of Alabama at Birming- 
ham). Stocks were cultured in F-12 (Cell-Gro, Mediatech) supplemented 
with 10%  FBS. All cells tested negative for mycoplasma contamination. 
NRK Colony Formation in Soft Agar 
TGF-~ activity was assayed by determining colony formation by NRK cells 
in soft agar assays as described (1) except assays were performed in 24 well 
tissue culture plates.  Briefly,  5%  Noble agar  (Difco,  Detroit,  MI)  was 
diluted 10-fold in 10% calf sernm/DME and 0.5 ml of this 0.5% agar dilu- 
tion was added per well to a 24-well tissue culture plate as a base layer, and 
allowed to harden. 0.2 ml sample containing 5 rig EGF was combined with 
0.6 rni 0.5% agar and 0.2 ml (2  ×  103) ofa NRK cell suspension in 10% 
calf serum/DME. 0.5 ml of this 0.3% agar sample solution was added to 
the cooled base layer and the plates were incubated for 7 d at 37°C, 5% 
CO2. The number of colonies greater than 62/~m (>8-10 cells) in diameter 
were counted. Experiments were performed in triplicate. 
BAE Cell Proliferation Assays 
BAE cells were plated at 5,000 cells per well in 1 ml of DME with 20% 
FBS in 24-well tissue culture plates and incubated overnight at 370C, 5% 
CO2. The cells were rinsed once in serum-free DME. Test samples in 0.5 
ml 2.5% FBS DME was added to each well in triplicate (day 0). On day 
2, cells received fresh aiiquots of test sample in 0.5 rni without removing 
the original media (to give a final volume of 1 ml). Cells were grown for 
another 2 d, then culture media was removed and cells were trypsinized with 
0.5  ml trypsin-EDTA (GIBCO BRL, Gaithersburg, MD) and harvested. 
The number of harvested cells was determined using a model ZM Coulter 
Counter (Coulter Electronics, Hialeah, FL). 
Preparation of  BAE Conditioned Media 
BAEs were plated at a density of 100,000  cells in a 25 cm  2 flask in 20% 
or 0.2% FBS/DME and incubated overnight at 37°C, 5% CO2. This den- 
sity was determined by comparing the ability of sTSP to activate latent 
TGF-/~ in sparse, sub-confluent, and confluent BAE cultures. This cell den- 
sity showed the greatest difference  in levels of active TGF-/~ between control 
and TSP-treated media. Flasks were rinsed once with 2 ml serum-free  DME 
and then test samples were added in 2.5 ml of DME with either 0.2 or 20% 
FBS as specified in the figure legends. The flasks were incubated for addi- 
tional times at 37°C,  5%  CO2.  Conditioned media was collected, cen- 
trifuged at 1,200 rpm for 5 rain to remove cellular debris, and stored at 4°C 
in polypropylene tubes for no more than 3 d before testing in NRK soft agar 
assay to determine TGF-8 activity. 
Activation of  Purified Recombinant Latent TGF-~ 
by sTSP 
13 nM sTSP was incubated with 2 nM purified recombinant latent TGF-/3 
in a  final volume of 0.5  ml in PBS for 2  h  at 37  or 4°C in siliconized 
microfuge tubes. Samples were then tested in NRK colony forming soft agar 
assays for TGF-/~ activity. 
Additional Materials 
The following items were purchased: e-aminocaproic acid (EACA), Aproti- 
nin, pepstatin A, and c~2 anti-plasmin (Sigma Chemical Co., St. Louis, 
MO), E-64, carboxypeptidnse, leupeptin (Caibiochem Corp., San Diego, 
CA), cystatin (Boehringer-Mannheim Corp.,  Indianapolis, IN).  Recom- 
binant TGF-~ (frGF-~) and purified recombinant latent TGF-~ (LTGF-/~) 
were generous gifts of Dr. Daniel Twardzik (Bristol-Myers Squibb, Seattle, 
WA). Tenascin was a gift of Dr. Harold Erickson, Duke University. Lami- 
nin was obtained from Dr. Magnus H66k (Institute of  Biotechnology, Hous- 
ton, TX). 
Antibodies 
Mouse anti-TSP  133 was raised a trairtst stripped TSP and developed using 
the mAb Core facility at UAB. This antibody is a IgG2b which recognizes 
the 50-kD chymotryptic fragment of  stripped TSP by Western blotting. Mab 
TSP-B7 ascites was raised against human platelet releasnte and is specific 
for TSP (11) (Sigma Chemical Co.). Mouse monoclonal and rabbit poly- 
clonal anti-TSP antibodies, raised a m~ingt native TSP, were generous gifts 
of Dr. Deane Musher, University of Wisconsin (Madison, Wisconsin) and 
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TSP Stripped of TGF-~ Activity Inhibits the Growth 
of BAE Cells 
Previous results from our lab and others have shown that TSP 
inhibits BAE cell growth (2, 42).  We observed that active 
TGF-/~ associated with the TSP was partially responsible for 
growth inhibition of BAE cells (34).  To examine whether 
TSP stripped of associated TGF-/~ (sTSP) activity inhibited 
BAE  growth,  we  repeated  cell proliferation assays  using 
sTSP. BAE cells were exposed to increasing concentrations 
of either native TSP (TGF-/3 activity associated with TSP), 
or  sTSP  (no  associated  TGF-/~  activity)  in  media  sup- 
plemented with 2.5 % FBS for a period of 4 d, at which time 
cell  number  was  determined.  Native  TSP and  sTSP  sig- 
nificantly inhibited the proliferation of BAE cells as com- 
pared  with  2.5%  FBS  alone  (Fig.  1).  Furthermore,  the 
dose-response curves were nearly identical for native and 
stripped TSPs. No significant cell death was observed. The 
inhibition of  BAE proliferation by TSP was concentration de- 
pendent with 1/tg/ml sTSP inhibiting 75 % of growth. Cells 
grown in the presence of sTSP assumed a more elongated, 
fibroblastic shape and had prominent nucleoli (Fig. 2 a) as 
compared with the polygonal cells in the 2.5% FBS media 
control  (Fig.  2  e).  Similarly,  TGF-/3  treated  cells  were 
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mouse anti-TSP antibodies to specific regions of native TSP were generous 
gifts of Dr. Vishva Dixit (University of Michigan). 
A  chicken  anti-TGF-/~ antibody  was purchased  from Oncomembrane 
(Seattle, WA) and a mouse monocional anti-TGF-/~  antibody was purchased 
from Genzyme Corp. (Cambridge, MA). Anti-vitronectin monoclonal and 
polyclonal antibodies were purchased from Telios (San Diego, CA). A poly- 
clonal anti-platelet factor 4 antibody was purchased from Atlantic Antibod- 
ies (Scarborough, ME). Mouse monoclonal anti-basic FGF (bFGF) was ob- 
tained  from Upstate Biotech.  Inc.  (Lake Placid,  NY). 
0  0.01  0.1  1  10 
pg/ml  Thrombospondin 
Figure L Inhibition of BAE cell proliferation by TSP. BAE cells 
were seeded at 5,000 cells per well in 24-well plates and incubated 
overnight in DME supplemented with 20% FBS. They were then 
washed with DME, and treated with varying concentrations of TSP 
(native or stripped) in DME containing 2.5% FBS on days 0 and 
2. Final cell number was determined on day 4. Cell number on day 
0 was 15,640 ±  2925 cells/well (arrow). Results are expressed as 
means of triplicate determinations  ±SD. 
elongated with numerous processes and prominent nucleoli 
(Fig. 2 c). 
A neutralizing antibody to TGF-/~ reversed the growth in- 
hibitory effects of sTSP by 42 % (Fig. 3). Addition of the neu- 
tralizing antibody to TGF-~ to wells containing sTSP also 
caused a partial reversion to a smaller, more polygonal cell, 
characteristic of normal BAE cells (Fig. 2 b). Similar results 
were obtained with both mouse and chick anti-TGF-/3 anti- 
bodies. In contrast, a polyclonai antibody (gift of Dr. Deane 
Mosher, University of Wisconsin, Madison, Wisconsin) and 
various mAbs specific for native TSP were not able to neu- 
tralize sTSP-mediated growth inhibition (data not shown). 
These results are similar to what was observed in growth in- 
hibition  experiments  using  native  TSP  (34).  Antibodies 
alone did not affect cell growth.  These data  suggest that 
growth inhibition of BAE cells by TSP stripped of associated 
TGF-/3 activity is at least partially due to a TGF-/~-dependent 
component. 
sTSP Activates TGF-I~  in BAE Conditioned Media 
Since  sTSP-mediated  BAE  growth  inhibition  is  partially 
TGF-/~ dependent, it is possible that sTSP incubation with 
BAE cells is causing activation of endogenous latent TGF-/~. 
TGF-/~ is secreted from endothelial cells as an inactive mole- 
cule (18) and it is not entirely clear how endothelial cell la- 
tent TGF-/~ is activated. To test the hypothesis that sTSP acti- 
vates latent TGF-/3 secreted by endothelial cells, sTSP was 
added to BAE cells in DME with 0.2% FBS for 0-48 h. Ali- 
quots of the conditioned media were tested in NRK colony 
forming soft agar assays for the presence of TGF-/~ activity. 
sTSP at0.4 #g/ml (0.9 nM) was able to increase colony form- 
ing activity in the conditioned media by 2-3-fold as com- 
pared with conditioned medium alone (Fig. 4). Increases in 
TGF-/~ activity were observed as early as 15 min after addi- 
tion of sTSP to cells and persisted above control levels for 
at least 48 h. Similar levels of  activation were observed when 
cells were conditioned in media where serum levels were 
raised from 0.2 to 20%, suggesting that sTSP-mediated stim- 
ulation of TGF-/3 activity is independent of serum factors. 
Stimulation of TGF-~ Activity Is Dependent 
on sTSP Concentration 
To assess whether the stimulation of TGF-/~ activity in BAE 
conditioned media was dependent on the concentration of 
sTSP present, varying doses of sTSP ranging from 10 ng to 
10 ttg were added to BAE cells in 2.5 ml of media. Concen- 
trations of sTSP between 40 and 400 ng/ml (100-1,000 ng 
added) were effective at stimulating NRK colony formation 
in soft agar (Fig. 5). The maximal response was repeatedly 
observed with  1 pg sTSP/25 cm  2 flask (0.4 #g/ml,  or 0.9 
nM).  When compared with recombinant TGF-/3 (YI'GF-/~), 
the level of maximal NRK colony formation induced by sTSP 
correlated to ~0.1  ng/ml of TGF-/3 activity. 
To rule out that the increase in TGF-/3 activity in the NRK 
soft agar assays was due to sTSP acting at the level of the 
NRK cells, we tested whether sTSP affected mature TGF-/3 
activity and whether anti-sTSP antibody 133, which inhibits 
sq'SP-stimulation  of TGF-/~ activity in the conditioned me- 
dium, affected TGF-/~ activity in the NRK assay.  As shown 
in Table I, there was no modulation of TGF-/3 activity by ei- 
ther grsP  or anti-TSP antibodies,  nor did  sTSP by itself 
Schultz-Cherry and Murphy-Ullrich Thrombospondin Activates TGF-B  925 Figure 2. The altered shape of 
BAE  cells  grown  in  sTSP 
is  partially  reversed  by 
anti-TGF-/3  antibody.  Ceils 
were seeded at 5,000 cells per 
well in 24-well plates, grown 
overnight in DME with 20% 
FBS,  washed,  and  refed  on 
days 0 and 2 with DME with 
2.5%  FBS  and  (a)  3  t~g/ml 
sTSP; (b) 3/~g/ml sTSP +  2.5 
ttg/ml mouse anti-TGF-/3;  (c) 
1 ng/ml recombinant TGF-/3; 
(d)  1  ng/ml  recombinant 
TGF-/3  +  2.5  t~g/ml  mouse 
anti-TGF-/3;  or  (e)  no  addi- 
tions.  Phase  micrographs  of 
these cells were photographed 
on day 4.  Bar,  100/~M. 
stimulate colony formation,  sTSP also does not activate the 
latent TGF-/3 present in the 0.2%  FBS  (Table I). 
Stimulation of TGF-[3  Activity in BAE Conditioned 
Media Is Specific for sTSP 
Other extracellular matrix proteins were tested for their abil- 
ity to activate endothelial cell secreted latent TGF-I//3. Equi- 
molar amounts of tenascin, fibronectin, BSA, or laminin did 
not stimulate TGF-/3 activation (Fig.  6). Basic FGF, in con- 
trast to a  previous report (13),  did not stimulate increased 
TGF-/~ activity in our  system (Fig.  6).  These results  show 
that  stimulation  of  TGF-/~  activity  in  BAE  conditioned 
medium  is  not  a  general  property  of extracellular  matrix 
molecules,  including  TGF-/$-binding  molecules  such  as 
fibronectin,  and therefore is a  specific property of gI'SE 
Antibodies to sTSP Inhibit Stimulation of TGF-~ 
Activity by sTSP 
To  eliminate  the  possibility  that  the  observed  increase  in 
TGF-~ activity was due to potential components associated 
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Figure 3.  Inhibition of BAE proliferation by sTSP is sensitive to 
anti-TGF-/3 neutralizing antibody. BAE cells were seeded at 5,000 
cells per well and incubated overnight  in DME with 20%  FBS, 
washed once with DME, and then grown in DME with 2.5% FBS 
supplemented on days 0 and 2 with either 3 ttg/ml sTSP, 3 #g/ml 
sTSP +  1 /zg/ml chicken anti-TGF-/3, or  1 ttg/ml  chicken anti- 
TGF-/3. Cell number on day 0 was 13,840 4- 600 cells per well. 
Cells were harvested and cell number per well was determined on 
day  4.  Results  are expressed  as  means of triplicate determina- 
tions 4-SD. 
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Figure 4. Kinetics of sTSP activation of TGF-/3 in 0.2% FBS BAE 
conditioned media (CM).  BAE cells seeded  at  1  x  105 cells/25 
cm  2 flask were grown overnight in DME supplemented with 0.2% 
FBS and 2 mM glutamine. 0.4 #g/ml sTSP (0.9 nM) was added to 
the flasks and incubated for 15 min to 8 h at 37°C, 5% CO2. Ali- 
quots (0.2 ml/sample) of conditioned medium with (~) or without 
(m) added sTSP were tested  in the NRK colony forming soft agar 
assay. Results are expressed  as means of triplicate determinations 
4-SD. 
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Figure 5. Activation of TGF-/3 in BAE conditioned media by sTSP 
is dose dependent. BAE cells were seeded at 1 x  l0  ~ cells/25 cm  2 
flask in DME with 20% FBS and incubated overnight. Flasks were 
rinsed once with DME, and then increasing amounts of sTSP in 2.5 
ml of DME with 0.2% FBS were incubated an additional  48 h. Ali- 
quots of these conditioned media were tested in the NRK soft agar 
colony forming assays to determine TGF-/3 activity (A). Different 
concentrations of rTGF-/3 were also tested in the same set of NRK 
soft agar assays (e). Results are expressed as means of triplicate 
determinations +SD. 
with sTSP, we attempted to block stimulation  with antibodies 
to TSE mAb 133 ascites, which recognizes an epitope in the 
50-kD chymotryptic fragment of sTSP, completely inhibited 
the  stimulation of TGF-# activity by sTSP (Fig.  7).  mAb 
TSP-B7 ascites, which is specific for the 70-kD core of plate- 
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Figure 6.  Stimulation of active TGF-/3 in BAE conditioned media 
(CM) is specific for sTSP. BAE cells seeded  at 1  x  105 cells/25 
cm  2 flask were grown overnight in DME supplemented with 20% 
FBS and then washed with DME. Then 0.4 #g/ml sTSP or equimo- 
lar amounts (0.9 nM) of various proteins were then added to 2.5 
ml of 20% FBS/DME and incubated with the cells for 48 h at 37°C, 
5% CO2. bFGF was used at 1 ng/2.5 ml. Aliquots of conditioned 
medium (0.2 ml/sample) were tested in NRK colony forming soft 
agar assays to determine TGF-B activity. Similar results were ob- 
tained when cells were conditioned in DME with 0.2% FBS. Results 
are expressed  as the means of triplicate determinations +SD. 
Schultz-Cherry  and  Murphy-Ullrich  Thrombospondin Activates TGF-13  927 I 
ii 
J 
o 
! 
N 
100 
50 
0 
¢/)  ~_  .- 
0  0  ~" 
Figure 7. Percent  inhibition  of sTSP-stimulated "I'GF-/~  activity by 
specific antibodies  to "I'GF-/~  and s'I'SP. BAE cells were seeded at 
1 x  105 cells/25  cm  2 flask in DME with 20% FBS and incubated 
overnight and then rinsed with serum-free DME.  1 #g sTSP, 1 #g 
sTSP +  1:100  rnAb TSP-B7 ascites,  1 #g sTSP +  1:100  mAb 133 
ascites,  1 #g sTSP +  10 #g mouse anti-TSP (DM, gift of Dearie 
Mosher), 1 #g sTSP +  2.5 #g mouse anti-TGF-/3 (Genzyme), 1 #g 
sTSP +  10 #g chick anti-TGF-/~ (Oncomembrane),  1 #g sTSP + 
rabbit anti-vitroneetin  (Telios),  1 #g sTSP +  1:100 control ascites, 
and  1 /~g s'rsP  +  10 #g goat anti-platelet  factor-4 (PF-4),  were 
added in 2.5 ml DME with 0.2%  FBS/flask  and incubated  48 h at 
370C, 5% CO2. Antibodies alone were also used as controls and 
had no effect.  Aliquots of conditioned medium (0.2  ml/sample) 
were tested in NRK colony forming soft agar assays to determine 
TGF-/~ activity.  Variations  among triplicates  was <10%. 
let TSP (11) also blocked this effect of sTSP.  However, an- 
other mAb which recognizes an epitope in the 70-kD frag- 
ment of native TSP (gift of Dr. Dearie Mosher) only inhibited 
sTSP activation of latent TGF-/3 by 32 %.  Antibodies alone 
Table L sTSP Does Not Affect the Activity of Mature 
rTGF-[3 or Stimulate TGF-(3 Activity in FBS 
Number of colonies formed 
EGF  39 +  1 
EGF  +  rTGF-/~  240  +  3 
EGF  +  rTGF-/~ sTSP  241  +  2 
EGF  +  sTSP  49 +  12 
EGF  +  sTSP  40 +  4 
EGF  +  0.2%  FBS  41  +  5 
EGF  +  0.2%  FBS  +  sTSP  41  +  4 
The NRK colony  forming  assay was performed as described in Materials and 
Methods. All samples contained  5 ng/ml  EGF in 10% calf serum/DME, except 
the samples in which EGF was in 0.2% FBS as indicated, sTSP (1 #g/ml) was 
preincubated with 1 ng/ml rTGF-~ for 2 h at 37"C, and compared for relative 
activity versus 1 ng/ml rTGF-/~ or 1 #g/ml sTSP. Anti-sTSP  antibody mAb 
133 (10 #g/ml) was pre-incubated with rTGF-/3 for 2 h, 370C before addition 
to NILK  cells in soft agar. sTSP (3 #g/rnl) was also incubated with 0.2%  FBS 
for 2 h, 37°C and tested for relative activity versus sTSP (3 #g/ml) or 0.2% 
FBS. All samples were tested in the NRK soft agar assay for 7 d at 37°C, 5% 
CO2.  Results are expressed as the means of triplicate determinations +SD. 
had no effect on these assays and did not interfere with rTGF- 
/~s ability to form colonies in soft agar (Table I). 
Colony  formation  was  also  TGF-/3  dependent,  since  a 
polyclonal chicken anti-TGF-/3 antibody and a  monoclonal 
mouse  anti-TGF-/3  neutralizing  antibody  completely  in- 
hibited colony formation (Fig. 7). These results show that the 
factor  activated  by  sTSP  in  BAE  conditioned  medium  is 
TGF- . 
In contrast,  antibodies  to vitronectin  (both  monoclonal 
and polyclonal), platelet factor-4, bFGF, and control ascites, 
did not inhibit the stimulation by sTSP (Fig. 7 and data not 
shown).  These data show that increases  in TGF-/3 activity 
observed in the NRK soft agar assays are not due to the pres- 
ence of commonly associated matrix and platelet proteins, 
but are dependent on sTSP and TGF-/3. 
sTSP Stimulation of TGF-f3 Activity in BAE 
Conditioned Medium Occurs Independently of 
Binding to the Cell Surface 
A proposed mechanism of latent TGF-~ activation in vivo is 
through binding to and internalization  of latent  TGF-/3 by 
mannose-6-phosphate receptors and subsequent processing 
in acidifying vesicles or processing by plasmin at the cell 
surface (12, 20, 21). Experiments were performed to deter- 
mine whether  sTSP requires  interactions  with cell  surface 
molecules to activate latent TGF-~.  After incubating BAE 
cells in DME with 0.2%  FBS overnight, the media was re- 
moved from the culture flasks and incubated in polypropyl- 
ene tubes in the presence or absence of sTSP (0.4/~g/ml) for 
the indicated times. This was done in direct comparison with 
sTSP incubated in the presence of cells. Aliquots of the con- 
ditioned medium were then tested in NRK colony forming 
soft  agar  assays  for  sTSP-mediated  activation  of TGF-fl. 
These data show that sTSP is able to activate TGF-fl in the 
absence of cells to a similar extent and with similar kinetics 
as shown in Fig. 4 in which sTSP was incubated in the pres- 
ence of cells (Fig. 4). Cell-conditioned media incubated with 
sTSP in the absence of cells demonstrated increased TGF-/~ 
activity as early as 15 min after addition of sTSP.  Maximal 
levels were reached by 2 h and persisted above baseline for 
at least 48 h (Fig. 8). Thus, in contrast to previously reported 
mechanisms of activation, TSP-mediated activation of latent 
TGF-/3 does not require interactions with cell surface mole- 
cules. 
sTSP-mediated Stimulation of TGF-f3 Activity ls 
Insensitive to Serine Protease lnhibitors 
Previous studies have shown that plasmin can activate latent 
TGF-/~ in vitro  (22,  23).  In cocultures  of endothelial  and 
smooth muscle cells, plasmin levels have been shown to be 
upregulated, thus activating latent TGF-/3 (40, 41). The com- 
mon motif is the involvement of a serine protease in the acti- 
vation of latent TGF-~.  Therefore,  we tested the effects of 
different  serine  protease  inhibitors  on  the  activation  of 
TGF-3 by sTSP in BAE-conditioned medium. TGF-~ activa- 
tion by sTSP was tested against a panel of serine protease in- 
hibitors  (Table  1/).  sTSP  (0.4  #g/ml)  was  incubated  with 
e-aminocaproic acid (EACA, 0.3 raM),  aprotinin (6 raM), 
and o~2-antiplasmin (0.6 #M).  The concentrations of these 
inhibitors were chosen based on previous studies (40) and 
dose-response assays.  These inhibitors  were unable to in- 
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Figure 8.  sTSP stimulation of TGF-/3 activity in BAE conditioned 
medium occurs independently of binding to the cell surface. BAE 
ceils  were  seeded  at  1  x  105 cells/25  cm  2 flask and incubated 
overnight  in  DME  supplemented  with  0.2%  FBS. The  cell- 
conditioned medium was removed, centrifuged to remove debris, 
and then incubated in sterile polypropylene tubes in the presence 
or absence of 0.4 #g/ml sTSP for 15 min to 8 h. Aliquots of media 
with ([3) or without (m) sTSP were tested in the NRK soft agar as- 
say to determine  TGF-/5 activity. All results are expressed as the 
means of triplicate determinations  +SD. 
hibit sTSP-mediated activation of TGF-/3 and had no effect on 
rTGF-/3 activity in soft agar assay. Due to evidence that TSP 
can interact with these serine proteases (7),  sTSP was also 
tested for associated plasmin and thrombin activity using en- 
zyme  assays  measuring  generation  of  chromogens  from 
specific substrates  (Boehringer-Mannheim Corp.).  No as- 
sociated plasmin or thrombin activity was detected in sTSP 
and there  was no generation of plasmin activity in  sTSP- 
conditioned medium as compared with control conditioned 
medium (data not shown). 
These  data  show  that  in  contrast  to  activation  of en- 
dothelial cell-derived latent TGF-/3 by bFGF or in coculture 
systems, latent TGF-/3 activation by sTSP does not involve 
serine proteases such as plasmin. 
Table II.  sTSP-mediated  Stimulation of TGF-[3 Activity Is 
Insensitive  to Serine Protease Inhibitors 
Percent  inhibition of 
sTSP-stimulated 
Tgf-/3 activity 
Protease  inhibitor  Concentration  (conditioned media) 
Percent  inhibition of 
rTGF/3 activity 
sTSP  + 
EACA  0.3  mM  0  0 
Aprotinin  6  mM  0  0 
ot2-antiplasmin  0.6 #M  0  0 
BAE cells were seeded at 1 x  105 cells/era 2 flask in DME with 20% FBS and 
incubated  overnight.  Flasks  were washed  with  DME,  and  1 pg sTSP  + 
protease  inhibitor was added to each flask in DME with either  2.5  ml 0.2% 
or 20%  FBS and then  incubated  with cells  an additional  48  h.  Aliquots  of 
conditioned medium were tested in NRK colony forming sott agar assays to 
determine TGF-B activity.  Recombinant TGF-/5 (5 ng/ml) was also incubated 
with the inhibitors  and assayed  for colony forming  activity.  Inhibitors alone 
were also added to the conditioned medium and had no effects on the assay 
(data not shown).  Results are representative  of several different experiments 
each performed  in triplicate.  Variations  among triplicates  were <10%. 
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Figure  9.  sTSP  activates 
purified  recombinant  latent 
TGF-/~. 13 nM sTSP was in- 
cubated  with  2  nM  purified 
recombinant latent TGF-/3 for 
2  h  at  40C  in  siliconized 
microfuge tubes.  4 mM HC1 
was used at an equal volume 
as sTSP as a positive control. 
The final volume was brought 
to 0.5 ml with PBS. Samples 
were  then  tested  in  NRK 
colony forming soft agar assay 
for "I'GF-/5  activity. Results are 
expressed as the means of trip- 
licate determinations  +SD. 
sTSP Can Activate Purified Recombinant 
Latent TGF-/3 
To determine if sTSP was activating latent TGF-/3 without the 
involvement of cell-secreted  factors,  sTSP  was  incubated 
with purified recombinant latent TGF-/3 for 2 h and then as- 
sayed for TGF-/3 activity, sTSP was able to activate recom- 
binant latent TGF-/3 at both 37 and 4°C (Fig. 9 and Schultz- 
Cherry, S., S. Ribeiro, J. E. Ranchalis, O. R. Twardzik, J. E. 
Murphy-Ullrich,  manuscript  in  preparation),  sTSP  at  13 
nM could activate approximately half of the acid-activatable 
latent TGF-/3. These results show that sTSP is able to activate 
latent  TGF-/3  directly,  without  the  involvement  of  cell- 
secreted factors such as proteases. 
Discussion 
In these studies, we describe a novel mechanism for activa- 
tion of latent TGF-/~ secreted by endothelial cells that is de- 
pendent upon the platelet and extracellular matrix protein, 
TSE sTSP inhibited BAE cell growth and caused morpholog- 
ical changes that were at least partially TGF-/3 dependent. 
This  led  us  to  propose  that  these  TGF-/%dependent  re- 
sponses were due to activation of endogenous BAE latent 
TGF-/3 by added sTSE Indeed, these studies show that incu- 
bation of sTSP with BAE cells or BAE conditioned medium 
generates  TGF-/3  activity as measured by EGF-dependent 
NRK colony formation in soft agar. Activation is related to 
the concentration of sTSP added to the cells and occurs fairly 
rapidly, within 15-120 min, and persists for at least 48 h. The 
increases in TGF-/3 activity occurring with sTSP treatment 
are most likely due to conversion of latent to active TGF-/3 
and are not due to increased synthesis of TGF-/3, since activa- 
tion of latent TGF-/3 by sTSP can occur in BAE conditioned 
media in the absence of cells. 
It is interesting that levels of TGF-/3 activity peak at 2-4 
h and do not increase with time. It is possible that after the 
initial  activation  of latent  TGF-/3  by  sTSP,  which  occurs 
within 15 min, the available binding sites for TGF-/3 on sTSP 
become saturated.  We have initial evidence suggesting the 
activation of latent TGF-/3 and the binding of active TGF-/3 
are due to the same region of TSP (Schultz-Cherry,  S., J. 
Lawler, J.  E. Murphy-Ullrich, manuscript in preparation). 
Schultz-Cherry  and Murphy-Ullrich  Thrombospondin Activates TGF-f3  929 Once the latent TGF-3 is activated by TSP, this region could 
bind to the newly activated TGF-3, potentially preventing 
further interactions. This may explain why the levels of ac- 
tive TGF-3 remain steady or are even slightly decreased at 
incubation times greater than 4 h. sTSP may also play a role 
in prolonging the half-life of active TGF-/3. 
Although several matrix proteins have been shown to bind 
active TGF-/~ (29, 34, 35, 44), activation of latent TGF-/~ is 
not a general property of extracellular matrix molecules or 
of TGF-3 binding proteins, since equimolar concentrations 
of tenascin, fibronectin, BSA, or laminin were unable to ac- 
tivate latent TGF-/~ secreted by endothelial cells. Serum co- 
factors do not appear to be important in sTSP-mediated acti- 
vation since activation occurs to a similar extent under high 
and low serum conditions. 
In these studies, STSP is apparently activating latent TGF-3 
secreted by BAE cells and not the latent TGF-/$ present in 
the FBS used in the medium, since TGF-/~ activity levels are 
not increased in FBS incubated with added sTSP as com- 
pared with control FBS. There is evidence that there are ac- 
tive TGF-/%TSP complexes normally present at low levels in 
these fluids, since when aliquots of FBS or BAE conditioned 
medium  are  applied  to  a  monoclonal  anti-TSP-CNBr 
Sepharose affinity  column, active TGF-/~ elutes with the TSP 
fractions (Ribeiro S., S. Schultz-Cherry, and J. E. Murphy- 
UUrich,  manuscript in preparation).  It is possible that the 
TSP present in the serum and the endogenous TSP secreted 
by the endothelial cells are already complexed with TGF-3 
and therefore lack available binding sites for interactions 
with latent TGF-3 synthesized during the course of the ex- 
periments. 
It  is  not  likely  the  sTSP-mediated  activation of latent 
TGF-3 is the result of sTSP acting as an adhesive protein or 
by causing increased internalization of TGF-3 by the NRK 
cells, since sTSP incubated with rTGF-/3 causes no increase 
in colony number as compared with rTGF-/~ alone and anti- 
sTSP antibody which neutralizes TSP-mediated activation of 
latent TGF-3 in conditioned medium had no effect on mature 
TGF-3 activity in the NRK assays. 
The 137 and 133 mAbs effectively inhibit TGF-3 activation 
by sTSP. These antibodies both recognize epitopes in the 
50-70 kD chymotryptic core of TSP (11 and Schultz-Cherry, 
S.,  S.  Ribeiro,  J.  Ranchilso,  O.  R.  Twardzik,  and J.  E. 
Murphy-UUrich, unpublished data). This is consistent with 
recent data from our lab that show that the 50-kD fragment 
of sTSP binds TGF-/3 and furthermore, that this 50-kD frag- 
ment can activate TGF-# in the conditioned media assays 
(Schultz-Cherry, S., and J. E. Murphy-Ullrich, manuscript 
in preparation). 
The observation that most antibodies raised against native 
platelet TSP were unable to inhibit sTSP-mediated activation 
of  TGF-B whereas a monoclonal raised against sTSP was able 
to completely block activation, suggests that bound TGF-/~ 
blocks the epitope recognized by mAb 133 in sTSP or alter- 
nately, that there are conformational differences between na- 
tive and stripped TSPs.  There may be definite conforma- 
tional requirements that determine TSP-TGF-3 interactions. 
These could involve disulfide-bond influenced tertiary struc- 
ture, since heat denaturation and reduction and alkylation of 
sTSP abolish sTSP activity in the conditioned medium assays 
(data not shown). These possibilities remain to be clarified. 
It has been shown previously in coculture systems (12, 21) 
that latent TGF-3 requires interactions at the cell surface for 
activation. In contrast, s'rSP  does not require interactions 
with the cell surface to activate TGF-3. Activation of latent 
TGF-/~ in BAE-conditioned medium removed from cells oc- 
curs with kinetics and to levels similar to what is observed 
when sTSP is incubated in the presence of cells. Further- 
more, sTSP is able to activate latent TGF-3 secreted by cells 
(CHO mutants pgsA 745) which lack TSP receptors (10, 33). 
In addition, data show that sTSP binds and activates purified 
recombinant latent TGF-/~ (Fig. 9 and Schultz-Cberry, S., S. 
Ribeiro, J.  Ranchilso, O.  R. Twardzik, and J. E.  Murphy- 
Ullrich, manuscript in preparation). These data show that 
activation most likely occurs through direct TSP-TGF-/~ in- 
teractions. 
The activation of latent TGF-3 by plasmin in endothelial 
cell systems is well documented (22, 23, 40, 41). In cocul- 
tures of endothelial cells and pericytes, activation of latent 
TGF-/3 was related to increased production of plasmin and 
was blocked by plasmin/serine protease inhibitors (40, 41). 
In contrast, activation of TGF-3 by sTSP in BAE conditioned 
media was not sensitive to serine protease or specific plas- 
rain inhibitors. Furthermore, we were unable to detect any 
plasmin activity associated with sTSP or any increases in 
plasmin activity in sTSP-treated BAE conditioned medium as 
compared to control conditioned medium. When inhibitors 
of other classes of protease (cysteine, aspartyl) were tested, 
we found either no effect or that the cysteine protease inhibi- 
tors, cystatin and E-64, inhibited TSP-mediated stimulation 
of TGF-3. However, cystatin was determined to be cytotoxic 
to the endothelial cells and E-64 was shown to interfere with 
the binding of TGF-/3 to sTSP. Furthermore, E-64 had no in- 
hibitory effect on sTSP-mediated  stimulation of BAE condi- 
tioned medium removed from the cells.  In addition, cal- 
pastatin,  a  specific  inhibitor  of  the  cysteine  protease, 
calpain, did not affect sTSP stimulation of TGF-fl activity in 
BAE conditioned medium. We also observed that sTSP was 
able to activate purified recombinant TGF-/~ with similar ki- 
netics when tested at both 4 and 37°C (Fig. 9 and Schultz- 
Cherry, S., S.  Ribeiro, J.  Ranchilso, O. R. Twardzik, and 
J. E. Murphy-Ullrich, manuscript in preparation). Together 
these data strongly suggest that srI'SP activation of latent 
TGF-3 occurs independently of proteolytic activity. 
sTSP-mediated  activation of TGF-/3 is not restricted to en- 
dothelial cells  since incubation of sTSP with MvlLu and 
CHO cells (wild-type and glycosaminoglycan-deficient  mu- 
tants) results in increased TGF-/~ activity (data not shown). 
Thus activation of latent TGF-3 by sTSP may be a general 
mechanism for paracrine control of TGF-3 activity by cells 
that synthesize TGF-/3 in the latent form. It will be important 
to examine the processing of the TGF-/3 once it is activated 
by sTSP. It is not known whether the pro-region of the latent 
molecule remains associated with the sTSP. 
Activation of TGF-3 by sTSP is efficient, since levels of 
colony formation in sTSP-treated  conditioned medium were 
80 % of the total alkaline-activatable TGF-/~ present in con- 
trol BAE conditioned medium (data not shown). The levels 
of TGF-3 activity generated by sTSP-treatment of BAE cells 
are physiologically significant (,0250 pg TGF-3 activity per 
,08  ×  105 cells over 48 h). These two observations strongly 
suggest that TSP interactions with latent TGF-/~ may play a 
substantive role in activation of TGF-3 in vivo. 
These  results  show that TSP  is  a  potent modulator of 
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tion to activating TGF-/3, TSP may serve as a carrier mole- 
cule to prolong the otherwise extremely short half-life of ac- 
tive TGF-/3 in body fluids (43). TSP may also serve to locally 
deposit active TGF-/3 at appropriate sites in tissues.  Since 
TSP is released in large quantities from stimulated platelets 
and its synthesis is rapidly induced by growth factors,  it is 
reasonable to suggest that TSP may enhance the ability of 
TGF-/3 to stimulate wound healing. Alternately, TSP-TGF-/3 
interactions  may  serve  to  facilitate  the  excessive  fibrosis 
stimulated by TGF-/5 in some pathological states. These pos- 
sibilities  remain to be explored. 
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